Last edition
News about "AstraZeneca"
Syneron Bio Raises USD 150 Million in Series B Funding
Syneron Bio raises USD 150 million in Series B to advance its Synova macrocyclic peptide platform and accelerate pipeline development towards clinical stages.
AstraZeneca | 06/04/2026 | By News Bureau
Imfinzi Combo Improves PFS in Unresectable Liver Cancer in Phase 3 EMERALD-3 Trial
Imfinzi-based combination improves progression-free survival and shows a trend towards overall survival benefit in unresectable liver cancer in the Phase 3 EMERALD-3 trial.
AstraZeneca | 04/04/2026 | By News Bureau
AstraZeneca Advances Rare Disease Pipeline with Positive HPP Phase III Data
Alexion, AstraZeneca Rare Disease, has reported positive results from its global Phase III clinical programme evaluating efzimfotase alfa (ALXN1850) in patients with hypophosphatasia (HPP), a rare inherited metabolic disorder.
AstraZeneca | 01/04/2026 | By Darshana | 103
AstraZeneca to Build Cell Therapy Hub and Innovation Centre in Shanghai
AstraZeneca has announced plans to set up a new cell therapy manufacturing and supply base along with an innovation centre in Shanghai, strengthening its presence in one of its key global markets.
AstraZeneca | 20/03/2026 | By Darshana | 112
EU Approves Imfinzi as First Perioperative Immunotherapy for Gastric and Gastroesophageal Cancers
The EU approval of Imfinzi is based on phase-III MATTERHORN trial results, which showed significant improvements in event-free and overall survival in early-stage gastric and gastroesophageal cancer patients.
AstraZeneca | 17/03/2026 | By Akanki
US Food and Drug Administration grants Priority Review to supplemental application for Enhertu to treat HER2-positive breast cancer patients with residual disease after neoadjuvant therapy, with decision expected in Q3 2026.
AstraZeneca | 10/03/2026 | By News Bureau
FDA clears 14-month, chemotherapy-free combination for first-line treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma, backed by positive Phase III AMPLIFY trial data.
AstraZeneca | 23/02/2026 | By News Bureau
The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.
AstraZeneca | 04/02/2026 | By News Bureau | 133
AstraZeneca Boosts Weight Management Portfolio via CSPC Collaboration
Under this agreement, Astrazeneca and CSPC Pharmaceuticals will initially progress four programmes, which utilise CSPC's advanced Artificial Intelligence (AI)-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology.
AstraZeneca | 31/01/2026 | By News Bureau | 190
AstraZeneca Commits USD 15 Billion to Expand Manufacturing and R&D in China
UK-based pharmaceutical major AstraZeneca has announced a USD 15 billion investment in China by 2030, marking its largest-ever commitment to the country. The investment is aimed at expanding the company’s research, development and manufacturing capabilities, reinforcing China’s role as a key pillar in AstraZeneca’s global growth strategy.
AstraZeneca | 30/01/2026 | By Darshana | 109
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy